Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Warner-Lambert acquired Agouron Pharmaceuticals in an all-stock merger valued at approximately $2.1B, with each Agouron share exchanged for roughly $60 of Warner-Lambert stock. Announced in January 1999, the deal closed on May 17, 1999. It gave Warner-Lambert the HIV protease inhibitor Viracept (nelfinavir) and Agouron's oncology discovery pipeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Warner-Lambert Company / Agouron Pharmaceuticals (this deal) | 1999 | $2.1B | 48 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 1999 deals · Infectious Disease deals